"We have a fully permitted project, significantly mitigating risk for potential investors. Our CK project will be the first gold mine in the state of Wyoming."
"We balance the need for speed in drug development with strict regulatory requirements by focusing on robust data, sound justifications and a well-structured technical package."
EXCLUSIVE SYNTHESIS BU LEADER (AC) & CATALOGUE APIS BU LEADER (RF), DIPHARMA FRANCIS
"Small molecule drugs dominate pharmaceutical development, holding almost 60% of the market in 2024, and FDA approvals for small molecules are expected to stay strong."
PROFESSOR & FORMER DEPARTMENT CHAIR - DEPARTMENT OF MINING ENGINEERING, THE UNIVERSITY OF UTAH
"Our focus is on advancing innovations in mine automation, efficient ventilation, mine design, and cooling systems to boost productivity and prioritize worker safety."
"For biotechs, finding the balance between appealing to the public and institutional investors will be a challenge, much like trying to balance a recipe with the right mix of ingredients for the perfect dish."
"New Jersey is home to eight of the top 10 global biopharmaceutical companies, nine of the top 10 R&D firms, and over 5,600 life sciences establishments. The State accounted for 43% of all novel FDA approvals in the past two years."
Ontario Mining and Toronto's Global Reach 2025 - Digital Interactive
2024 was marked a ‘super year’ for elections by the UN, with 72 countries and almost half the world’s population heading to the polls, impacting the global mining sector with each vote cast. This election uncertainty was accompanied by familiar issues for Ontario’s miners, with labor shortages, challenging equity markets, and cost inflation dominating the discourse of industry professionals across the value chain.